GlassScriptPhysician profile
Rita A Jermyn
NPI 1811140627
$86,957.71
in general payments reported to CMS, 2019-2025
33 companies · $4,030 in 2025
The $4,030 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $8,071 · 2021: $7,196 · 2022: $5,080 · 2023: $6,049 · 2024: $7,453 · 2025: $4,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $3,801 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,631.50 |
| Food and Beverage | $3,801.10 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45,367.51 | 2019-2024 | |
| Abbott Laboratories | $21,516.30 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Kestra Medical Technology Services, INC. | $9,006.69 | 2022-2025 | Assure Wcd |
| Edwards Lifesciences Corporation | $4,311.50 | 2022-2023 | |
| Boston Scientific Corporation | $1,222.00 | 2019 | |
| Alnylam Pharmaceuticals INC. | $867.46 | 2020-2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $834.81 | 2022-2025 | |
| Akcea Therapeutics, INC. | $690.23 | 2019-2021 | |
| Vifor Pharma, INC. | $392.56 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $337.69 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.79 | 2020-2025 | Jardiance |
| Becton, Dickinson and Company | $275.00 | 2021 | |
| Covidien LP | $266.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $250.00 | 2022-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $204.65 | 2022-2025 | Camzyos, Eliquis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $150.00 | 2023 | |
| Scpharmaceuticals INC. | $130.97 | 2023-2025 | |
| United Therapeutics Corporation | $127.52 | 2020-2021 | |
| Amarin Pharma, INC. | $125.00 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $122.89 | 2024-2025 | Uptravi, Opsumit |
| Cvrx, INC. | $91.97 | 2025 | Barostim Neo System |
| Arbor Pharmaceuticals, INC. | $81.30 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $71.68 | 2020-2025 | Lokelma |
| Merck Sharp & Dohme LLC | $55.89 | 2021-2023 | Verquvo |
| Abiomed | $48.75 | 2025 | |
| Impulse Dynamics (USA) INC. | $45.86 | 2021-2022 | |
| Bridgebio Pharma, INC. | $35.52 | 2025 | Attruby |
| Sensible Medical Innovations INC | $21.49 | 2025 | Reds System |
| Pfizer INC. | $17.68 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Jermyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.